Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Address
40 ERIE STREET
CAMBRIDGE, MA 02139
Founded
2014
Number of Employees
526
Website
http://www.intelliatx.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)